Czech Recommendations for Biological Therapy of Severe Plaque Psoriasis (Approved by the Committee of the Czech Society of Dermatology and Venereology)

1. AITHAL, G. P. Hepatotoxicity related to antirheumatic drugs. Nat. Rev. Rheumatol., 2011, 7, 3, p. 139–150.

2. VAN ASSEN, S., AGMON-LEVIN, N., ELKAYAM, O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis., 2011, 70, p. 414–422.

3. BELL, G. M., REYNOLDS, G., ISAACS, J. D. Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat. Rev. Rheumatol., 2011, 7, p. 507–516.

4. BENÁKOVÁ, N., ŠTORK, J. et al. Léčba psoriázy biologiky. Konsenzuální doporučené postupy České dermatologické společnosti ČLS JEP 2006. Čes-slov Derm., 2006, 81, 4, s. 1–11.

5. BEN-HORIN, S., YAVZORI, M., KATZ, L. et al. Adalimumab level in breastmilk of a nursing mother. Clin. Gastroenterol. Hepatol., 2010, 8, 5, p. 475–476.

6. BEYER, M., STEINHOFF, M., ANAGNOSTOPOULOS, I. et al. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients? J. Dtsch. Dermatol. Ges., 2009, 7, 3, p. 191–194.

7. BISSONNETTE, R., POULIN, Y., GUENTHER, L. et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J. Eur. Acad. Dermatol. Venereol., 2011, 25, 12, p. 1402–1408.

8. BOEHNCKE, S., SALGO, R., GARBARAVICIENE, J. et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J. Eur. Acad. Dermatol., 2011, 25, p. 1187–1193.

9. BOEHNCKE, W. H., KATSAMBAS, A., ORTONNE, J. P. et al. EADV preceptorship: advances in dermatology. J. Eur. Acad. Dermatol., 2010, 24, suppl. 5, p. 2–24.

10. DEN BROEDER, A. A., CREEMERS, M. C., FRANSEN, J. et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J. Rheumatol., 2007 34, 4, p. 689–695.

11. BRUNASSO, A. M., PUNTONI, M., GULIA, A., MASSONE, C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology, 2011, 50, 9, p. 1700–1711.

12. CAPORALI, R., BOBBIO-PALLAVICINI, F., ATZENI F. et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res., 2010, 62, 6, p. 749–754.

13. CARROLL, M. B., HOLMES, R. Safety of anti-tumor necrosis factor therapy in patients with chronic hepatitis B. Hep B Annual., 2009, 6, p. 89–109.

14. CASSANO, N., VESTITA, M., APRUZZI, D. et al. Alcohol, psoriasis, liver disease and anti-psoriasis drugs. Int. J. Dermatol., 2011, 50, p. 1323–1331.

15. CLEMMENSEN, A., SPON, M., SKOV, L. et al. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent exposed patients with psoriasis vulgaris. J. Eur. Acad. Dermatol., 2011, 25, p. 1037–1040.

16. CLOWSE, M. E. B. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int. J. Womens Health, 2010, 2, p. 199–209.

17. CULLEN, G., KROSHINSKY, D., CHEIFETZ, A. S. et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment. Pharmacol. Ther., 2011, 9 p., online early.

18. DANILA, M. I., PATKAR, N. M., CURTIS, J. R. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr. Opin. Rheumatol., 2008, 20, p. 327–333.

19. DI LERNIA, V. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments. Int. J. Dermat., 2010, 49, 6, p. 631–635.

20. DI LERNIA, V., ALBERTINI,G. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe? Br. J. Dermatol., 2010, 162, 5, p. 1147–1148.

21. DING, T., LEDINGHAM, J., LUQMANI, R. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 2010, 49, p. 2217–2219 a suppl., 2010, 9, p. 14.

22. DJOKANOVIC, N., KLIEGER-GROSSMANN, C., PUPCO, A. et al. Safety of infliximab use during pregnancy. Reprod. Toxicol., 2011, 32, 1, p. 93–97.

23. DOMM, S., CINATL, J., MROWIETZ, U. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br. J. Derm., 2008, 159, p. 1217–1228.

24. DOMMASCH, E. D., ABUABARA, K., SHIN, D. B. et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. J. Am. Acad. Dermatol., 2011, 64, p. 1035–1050.

25. DREIHER, J., KRESCH, F. S., COMANESHTER, D. et al. Risk of herpes zoster in patients with psoriasis treated with biologic drugs. J. Eur. Acad. Dermatol., 2011, online early.

26. DRIESSEN, R. J. B., BOEZEMAN, J. B., VAN DE KERKHOF, P. C. M. et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br. J. Derm., 2009 160, p. 670–675.

27. EMEA. Enbrel, aktualizace 26/09/2011. Dostupné na www: http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf

28. EMEA. Humira, aktualizace 17/11/2011. Dostupné na

www:http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000481/WC500050870.pdf

29. EMEA. Remicade, aktualizace 13/12/2011. Dostupné na www:

http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf

30. EMEA. Stelara, aktualizace 20/09/2011. Dostupné na www. http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf

31. EMER, J. J., FRANKEL, A., ZEICHNER, J. A. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. J. Clin. Aesthet. Dermatol., 2010, 3(8), p. 20–26.

32. ESPOSITO, M., MAZZOTTA, A., SARACENO, R. et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int. J. Immunopathol. Pharmacol., 2009, 22, p. 219–225.

33. FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. 2011. Dostupné na www: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm

34. FDA Use-in-Pregnancy Ratings. Dostupné na www: http://www.perinatology.com/exposures/Drugs/FDACategories.htm.

35. FROMONT, A., DE SEZE, J., FLEURY, M. C. et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine, 2009 Feb, 45, 2, p. 55–57.

36. GNIADECKI, R., KRAGBALLE, K., DAM T. N. et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patiens with psoriasis vulgaris. Br. J. Dermatol., 2011, 164, p. 1091–1096.

37. GRATTON, D., SZAPARY, P., GOYAL, K. et al. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch. Dermatol., 2011, 147, 10, p. 1197–1202.

38. GUENTHER, L. C. Combination Therapy of Biologics with Traditional Agents in Psoriasis. Skin Therapy Lett., 2011, Jun, 16, 6, p. 1–3.

39. HÄRLE, P., STRAUB, R. H., FLECK, M. Elective surgery in rheumatic disease and immunosuppression: to pause or not. Rheumatol., 2010, 49, 10, p. 1799–1800.

40. HÄRLE, P., STRAUB, R. H., FLECK, M. Perioperative management of immunosuppression in rheumatic diseases – what to do? Rheumatol. Int., 2010, 30, 8, p. 999–1004.

41. HERNANDEZ CRUZ, B., CETNER, A. S., JORDAN, J. E. et al. Tuberculosis in the age of biologic therapy. J. Am. Acad. Dermatol., 2008, 59, p. 363–380.

42. HOFFMANN, J. H. O., HARTMANN, H., ENK, A. H. Autoantibodies in psoriasis as predictors for loss-of-response and anti-infliximab antibody induction. Br. J. Dermatol., 2011, Aug 1. doi: 10.1111.

43. HUANG, W., CORDORO, K. M., TAYLOR, S. L. et al.To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J. Am. Acad. Dermatol., 2008, 58, 6, p. 970–977.

44. HUSA, P., PLÍŠEK, S., ŠPERL, J. et al. Diagnostika a léčba chronické hepatitidy B. Doporučený postup České hepatologické společnosti a Společnosti infekčního lékařství ČLS J. E. Purkyně. Dostupné na www: http://www.infekce.cz/DoporVHB09t.htm.

45. CHUNG, S. J., KIM, J. K., PARK, M. CH. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J. Rheumatol., 2009, 36, 11, p. 2416–2420.

46. JANSEN, T. L. When rheumatology meets hepatology: Are anti-TNFs safe in hepatitis B virus carriers? Arthritis Res. Therapy, 2010, 12, p. 103.

47. JARAND, J., ZOCHODNE, D. W., MARTIN, L. O. et al. Neurological complications of infliximab. J. Rheumatol., 2006, 33, p. 1018–1020.

48. KAWAKAMI, K., IKARI, K., KAWAMURA, K. et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatol., 2010, 49, 2, p. 341–347.

49. VAN DE KERKHOF, P. C. Novel biologic therapies in development targeting IL-12/IL-23. J. Eur. Acad. Dermatol., 2010, 24 (suppl. 6), p. 5–9.

50. KEYSTONE, E. C., PAPP, K. A., WOBESER, W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J. Rheumatol., 2011, 38, 7, p. 1234–1243.

51. KWAN, Y. L., MAHADEVAN, U. Inflammatory Bowel Disease and Pregnancy: An Update. Expert Rev. Clin. Immunol., 2010, 6, 4, p. 643–657.

52. LEBWOHL, M., BAGEL, J., GELFAND, J. M. et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J. Am. Acad. Dermatol., 2008, 58, 1, p. 94–105.

53. LECLUSE, L. L. A., DOWLATSHAHI, E. A., LIMPENS, J. M. et al. Etanercept. An overview of dermatologic adverse events. Arch. Dermatol., 2011, 147, p. 79–94.

54. LECLUSE, L. L., DE GROOT, M., BOS, J. D. et al. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br. J. Dermatol., 2009, 161, 4, p. 948–951.

55. Legionnaire’s disease. Dostupné na:

http://www.nlm.nih.gov/medlineplus/ency/article/000616.htm.

56. LOZERON, P., DENIER, C., LACROIX, C. et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch. Neurol., 2009, 66, 4, p. 490–497.

57. VAN LÜMIG, P., DRIESSEN, R., BERENDS, M. et al. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J. Eur. Acad. Dermatol. Venereol., 2011, Mar 24. doi: 10.1111/j.1468-3083.2011.04044.x. [Epub ahead of print].

58. VAN LÜMIG, P. P., DRIESSEN, R. J., ROELOFS-THIJSSEN, M. A. et al. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. Br. J. Dermatol., 2011, 165, 2, p. 375–382.

59. MARTIN, P. L., SACHS, C., IMAI, N. et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res. B. Dev. Reprod. Toxicol., 2010, 89, 5, p. 351–363.

60. MEHTA, N. N., AZFAR, R. S., SHIN, D. B. et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur. Heart J., 2010, 31, p. 1000–1006.

61. MENTER, A., GOTTLIEB, A., FELDMAN, S. R. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol., 2008, 58, p. 826–850.

62. MENTER, A., KORMAN, N. J., ELMETS, C. A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol., 2011, 65, p. 134–174.

63. MROWIETZ, U., KRAGBALLE, K., REICH, K. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch. Dermatol. Res., 2011, 303, p. 1–10.

64. MROWIETZ, U., KRAGBALLE, K., NAST, A. et al. Strategies for improving the quality of care in psoriasis with the use of treatment goals - a report on an implementation meeting. J. Eur. Acad. Dermatol., 2011, 25, suppl. 3, p. 1–13.

65. NAST, A., BOEHNCKE, W. H., MROWIETZ, U. et al. S3-Guidelines on the treatment of psoriasis vulgaris. Update 2011. JDDG, 2011, 9, suppl. 2, p. S1–S95.

66. NESTLE, F. O., KAPLAN, D. H., BARKER, J. Psoriasis. N. Engl. J. Med., 2009, 361, p. 496–509.

67. Noiles, K., Vender, R. Biologic survival. J. Drugs Dermatol., 2009, 8, 4, p. 329–333.

68. ORTONNE, J. P., CHIMENTI, S., REICH, K. et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J. Eur. Acad. Dermatol., 2011, 25, p. 1012–1020.

69. PALLER, A. S., SIEGFRIED, C., LANGLEY, R. G. et al. Etanercept treatment for children and adolescens with plaque psoriasis. N. Engl. J. Med., 2008, 358, p. 241–251.

70. PAPP, K. A. et al. Canadian Guidelines for the Management of Plaque Psoriasis. 2009; June. Dostupné na: http://www.dermatology. ca/guidelines/cdnpsoriasisguidelines.pdf.

71. PATHIRANA, D., ORMEROD, AD., SAIAG, P. et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol., 2009, 23, p. 1–70.

72. PERLMUTTER, A., MITTAL, A., MENTER, A. Tuberculosis and tumour necrosis factor-a inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br. J. Derm., 2009, 160, p. 8–15.

73. PIERINGER, H., STUBY, U., BIESENBACH, G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin. Arthritis Rheum., 2007, 36, 5, p. 278–286.

74. PRINZ, J. C. Autoimmune-like syndromes during TNF blockade: does infection have a role. Nat. Rev. Rheumatol., 2011, 7, p. 429–434.

75. PUIG, L., CARRASCOSA, J. M., DAUDÉN E. Spanish evidence-based guidelines on the treatment of moderate to severe psoriasis with biologic agents. Actas Dermosifiliogr., 2009, 100, p. 386–413.

76. RAHIER, J. F., MOUTSCHEN, M., VAN GOMPEL, A. et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology, 2010, 49, p. 1815–1827.

77. ROOS, J. C., OSTOR, A. J. Neurological complications of infliximab. J. Rheumatol., 2007, 34, 1, p. 236–237.

78. RYAN, C., LEONARDI, C. L., KRUEGER, J. G. et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events. A meta-analysis of randomized controlled trials. JAMA, 2011, 306, p. 864–871.

79. SALMON-CERON, D., TUBACH, F., LORTHOLARY, O. et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann. Rheum. Dis., 2011, 70, p. 616–623.

80. SANTOS-JUANES, J., COTO-SEGURA, P., MAS-VIDAL, A. et al. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br. J. Dermatol., 2010, 162, p. 1144–1146.

81. SARACENO, R., SCHIPANI, C., MAZZOTTA, A. et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol. Res., 2008, 57, p. 290–295.

82. SMITH, C. H., ANSTEY, A. V., BARKER, J. N. et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol., 2009, 161, p. 987–1019.

83. SOLOVIC, I., SESTER, M., GOMEZ-REINO, J. J. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur. Respir. J., 2010, 36, p. 925–949.

84. STROBER, B., BERGER, E., CATHER, J. et al. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. J. Am. Acad. Dermatol., 2009, 61, p. S1–S46.

85. TAN, C. S., KORALNIK, I. J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol., 2010, 9, 4, p. 425–437.

86. TRACEY, D., KLARESKOG, L., SASSO, E. H. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther., 2008, 117, p. 244–279.

87. VENCOVSKÝ, J. a výbor České revmatologické společnosti. Bezpečnost biologické léčby – doporučení České revmatologické společnosti. Čes. Revmatol., 2009, 17, s. 146–160.

88. VERSTAPPEN, S. M. M., KING, Y., WATSON, K. D. et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis., 2011, 70, p. 823–826.

89. VINET, E., PINEAU, C., GORDON, C. et al. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum., 2009, 15, 61, 5, p. 587–592.

90. WINTHROP, K. L., CALABRESE, L. H. Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann. Rheum. Dis., 2011, 70, p. 1701–1703.

91. WOLFE, F., MICHAUD, K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum., 2007, 56, p. 2886–2895.

92. WU, S. AAD 69th Annual Meeting. Abstract P400. February, 2011.

93. Zápis z jednání Sekce pro tuberkulózu ČPFS dne 1. 12. 2005. Dostupné na www:

http://www.pneumologie.cz/zapisy/2005/sekce-TBC-20051201.php.